SecurityATRC / AtriCure, Inc. (04963C209)
IndustrySurgical and Medical Instruments and Apparatus
Common Shares Outstanding35,040,049 shares (as of 2018-03-31)
Total Insiders18
Total Directors12
Total Officers7

Stock Insider Trading (from SEC Form 4)

AtriCure, Inc. insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.

ATRC / AtriCure, Inc. insiders include Privitera Salvatore Noznesky Justin J, WHITE ROBERT S., GROVES REGINA E, LUX ANDREW L, JOHNSTON RICHARD M, Lanning Mark R, WEHRWEIN SVEN, Wade M. Andrew, ROBARDS KAREN P, JOHNSON B KRISTINE, CARREL MICHAEL H, Collar Mark A, Drake Scott William, Krell Elizabeth D, Hooven Michael D, Kennedy Patricia J, and Seith Douglas J, .

Insider Roster

Insider Dir Off 10% Shares Owned
X 13,826
X 11,026
Lanning Mark R Director
X 106,026
X 16,190
X 15,690
Drake Scott William Director
X 22,026
Collar Mark A Director
X 74,288
CARREL MICHAEL H President, CEO, & Director, Director
X X 711,896
Noznesky Justin J SVP, Mktg & Business Develop
X 131,920
Krell Elizabeth D Director
X 19,967
Privitera Salvatore Chief Technology Officer
X 87,174
Wade M. Andrew SVP and CFO
X 179,757
Seith Douglas J Chief Operating Officer
X 257,239
LUX ANDREW L SVP, Ops & Quality
X 66,549
X 5,805
Hooven Michael D Director
X 553,892
Kennedy Patricia J VP and GM, International

Transaction History

Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.

Form Insider Code 10b-5 Direct Share
Post Value
2018-05-22 4 Collar Mark A A D 5,221 74,288
2018-05-22 4 Drake Scott William A D 5,221 22,026
2018-05-22 4 GROVES REGINA E A D 5,221 15,690
2018-05-22 4 JOHNSON B KRISTINE A D 5,221 16,190
2018-05-22 4 Lanning Mark R A D 5,221 106,026
2018-05-22 4 WEHRWEIN SVEN A D 5,221 11,026
2018-05-22 4 WHITE ROBERT S. A D 5,221 13,826
2018-05-15 4 Noznesky Justin J S D 23.05 -4,000 131,920 3,040,756
2018-05-16 4 CARREL MICHAEL H G D -325 711,896
2018-05-08 4 Krell Elizabeth D S D 22.82 -10,000 19,967 455,647
2018-05-07 4 Krell Elizabeth D M D 9.30 10,000 29,967
2018-03-13 4 Krell Elizabeth D S D 20.00 -10,000 19,967 399,340
2018-03-12 4 Krell Elizabeth D M D 14.17 10,000 29,967
2018-03-01 4 Seith Douglas J F D 17.71 -19,677 257,239
2018-03-01 4 Seith Douglas J A D 35,996 276,916
2018-03-01 4 Wade M. Andrew F D 17.71 -14,969 179,757
2018-03-01 4 Wade M. Andrew A D 35,996 194,726
2018-03-01 4 CARREL MICHAEL H F D 17.71 -19,740 712,221
2018-03-01 4 CARREL MICHAEL H A D 95,285 731,961
2018-03-01 4 Noznesky Justin J F D 17.71 -14,803 135,920
2018-03-01 4 Noznesky Justin J A D 25,726 150,723
2018-03-01 4 Privitera Salvatore A D 21,174 87,174
2018-03-02 4 Lanning Mark R M D 10.10 10,000 100,805
2018-03-01 4 Drake Scott William P D 17.64 11,000 16,805 296,440
2018-03-01 4 GROVES REGINA E P D 17.43 1,000 10,469 182,475
2018-02-15 4 Noznesky Justin J S D 17.03 -4,000 124,997 2,128,699
2018-01-24 4 CARREL MICHAEL H F D 17.55 -33,167 636,676
2018-01-24 4 Seith Douglas J F D 17.55 -3,275 240,920
2018-01-24 4 Wade M. Andrew F D 17.55 -3,791 158,730
2018-01-18 4 Collar Mark A M D 13.31 25,000 69,067
2018-01-06 4 Noznesky Justin J F D 17.99 -3,182 128,997
2017-12-29 4 CARREL MICHAEL H A D 15.50 547 669,843
2017-12-29 4 Seith Douglas J A D 15.50 328 244,195
2017-12-29 4 Wade M. Andrew A D 15.50 571 162,521
2017-11-28 4 CARREL MICHAEL H G D -1,400 669,296
2017-11-30 4 Wade M. Andrew S D 18.41 -2,000 161,950 2,981,500
2017-11-30 4 Wade M. Andrew M D 11.65 2,000 163,950
2017-11-08 4 JOHNSON B KRISTINE P D 18.36 1,500 10,969 201,391
2017-09-14 4 Collar Mark A M D 13.31 25,000 44,067
2017-08-22 4 Krell Elizabeth D S D 22.40 -10,000 19,967 447,261
2017-08-21 4 Krell Elizabeth D M D 8.04 10,000 29,967
2017-08-02 4 Noznesky Justin J G D -3,000 132,179
2017-07-24 4 Privitera Salvatore A D 60,000 66,000
2017-06-30 4 Seith Douglas J A D 16.32 888 243,867
2017-06-30 4 Wade M. Andrew A D 16.32 529 161,950
2017-06-30 4 LUX ANDREW L A D 16.32 960 66,549
2017-06-30 4 CARREL MICHAEL H A D 16.32 612 670,696
2017-06-13 4 Seith Douglas J S D 21.39 -58,112 242,979 5,197,321
2017-06-13 4 Seith Douglas J M D 6.73 25,000 301,091
2017-06-13 4 Seith Douglas J M D 6.27 21,100 276,091
Open market or private purchase of non-derivative or derivative security
Open market or private sale of non-derivative or derivative security
Grant, award, or other acquisition of securities from the company (such as an option)
Conversion of derivative
Sale or transfer of securities back to the company
Payment of exercise price or tax liability using portion of securities received from the company
Gift of securities by or to the insider
Equity swaps and similar hedging transactions
Exercise or conversion of derivative security received from the company (such as an option)
A transaction voluntarily reported on Form 4
Other (accompanied by a footnote describing the transaction)

Related Articles

HRTX : Heron Therapeutics Analysis and Research Report

2018-05-25 - Asif

Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...

ACIA: Acacia Communications Analysis and Research Report

2018-05-25 - Asif

Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

Related News Stories

AtriCure's (ATRC) CEO Mike Carrel on Q1 2018 Results - Earnings Call Transcript

2018-04-29 seekingalpha
Good afternoon, and welcome to AtriCure's First Quarter 2018 Earnings Conference Call. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. (3-0)

AtriCure's (ATRC) CEO Mike Carrel on Q4 2017 Results - Earnings Call Transcript

2018-02-27 seekingalpha
Good afternoon. And welcome to AtriCure’s Fourth Quarter and Year End 2017 Earnings Conference Call. At this time, all participants are in a listen-only mode. We will be facilitating a question-and-answer session towards the end of today’s call. As a reminder, this call is being recorded for replay purposes. (3-0)

Biotech Daily Digest For January 16th

2018-01-16 seekingalpha
Biotech is rising in 2018 but still lags other sectors that will see more direct impacts from the recently passed tax legislation. (685-1)